Pain Reports最新文献

{"title":"Serum neurofilament light chain in fibromyalgia: comparative evidence of neuronal injury across chronic pain conditions.","authors":"Joel Fundaun, Eoin Kelleher, Lydia Coxon, Amanda Wall, Jishi John, Kurtis Garbutt, Andreas C Themistocleous, Yuki Terajima, David L Bennett, Katy Vincent, Anushka Irani, Annina B Schmid","doi":"10.1097/PR9.0000000000001423","DOIUrl":"10.1097/PR9.0000000000001423","url":null,"abstract":"<p><strong>Introduction: </strong>Evidence increasingly shows small nerve fibre pathology in subsets of people with fibromyalgia through skin biopsy, corneal confocal microscopy, and microneurography. However, blood-based biomarkers of ongoing neuronal damage, particularly neurofilament light chain (NfL), an axonal structural protein, are not well established.</p><p><strong>Objectives: </strong>The aim of this study was to evaluate serum NfL concentrations in fibromyalgia compared with other chronic pain conditions and assess their relationship with neuropathic-like pain.</p><p><strong>Methods: </strong>We measured serum NfL using Simoa SR-X NF Light v2 digital-immunoassay in 60 participants with fibromyalgia, 61 with endometriosis (another traditionally considered non-neuropathic pain condition), 24 with small fibre neuropathy (a recognised neuropathic pain condition), and 30 healthy controls. Serum NfL concentrations were compared between the groups controlling for age and body mass index. Neuropathic-like pain was assessed using the painDETECT questionnaire for fibromyalgia and endometriosis and NeuPSIG grading criteria for small fibre neuropathy.</p><p><strong>Results: </strong>Compared with healthy controls (mean concentration = 6.77 pg/mL, Z-score = -1.15), serum NfL concentrations were significantly elevated in fibromyalgia (mean concentration = 8.52 pg/mL <i>P</i> = 0.048; Z-score = -0.30, and <i>P</i> = 0.006) and small fibre neuropathy (mean concentration = 8.98 pg/mL, <i>P</i> = 0.004; Z-score = 0.23, <i>P</i> = 0.0001), with endometriosis representing an intermediate phenotype (mean concentration = 5.57 pg/mL, <i>P</i> = 0.44; Z-score = -0.41, <i>P</i> = 0.024). Using PainDETECT, 44% of fibromyalgia and 26% of endometriosis participants met likely neuropathic pain criteria; using NeupSIG grading, 96% of small fibre neuropathy participants met probable/definite criteria.</p><p><strong>Conclusion: </strong>Our study provides serological evidence of nerve pathology in fibromyalgia at comparable levels with small fibre neuropathy, although this did not correlate with neuropathic-like pain presence or severity. These findings highlight the need for subgroup-specific treatment strategies.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"11 2","pages":"e1423"},"PeriodicalIF":3.1,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13016184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147522793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating controlled direct treatment effects on pain intensity using structural mean models.","authors":"Rui Wang, Patrick J Heagerty, Kwun Chuen Gary Chan, Pradeep Suri","doi":"10.1097/PR9.0000000000001409","DOIUrl":"10.1097/PR9.0000000000001409","url":null,"abstract":"<p><strong>Introduction: </strong>Without valid inclusion of concurrent analgesic use, the primary analyses of pain intensity in pain randomized controlled trials (RCTs) may produce diminished estimated treatment effects.</p><p><strong>Methods: </strong>We used contemporary causal inference methods to reanalyze RCT data examining the effect of epidural steroid injection (ESI) as an example of a pain treatment. Specifically, we define an \"attributable to ESI estimand,\" which is the controlled direct effect of ESI. We used a simple composite pain intensity outcome, the QPAC_1.5, and structural mean models (SMM) to estimate the target estimand. Compared with traditional methods such as strict intention to treat analysis (strict ITT), SMMs can account for analgesic use without assuming no unmeasured confounding between the analgesic use and the outcome. We estimated treatment effects of ESI on leg pain intensity using the numeric rating scale with strict ITT, 3 SMM estimating methods (estimating equations, g-estimation, and generalized method of moments), and the QPAC_1.5.</p><p><strong>Results: </strong>The treatment effect of ESI on leg pain intensity using strict ITT was -0.751 numeric rating scale points (95% confidence interval [CI]: -1.287 to -0.214). Estimates for the attributable to ESI estimand were -0.864 (95% CI: -3.207 to 1.478) for estimating equations, -0.935 (95% CI: -1.779 to 0.090) for g-estimation, -0.653 (95% CI: -1.218 to -0.089) for generalized method of moments, and -0.930 (95% CI: -1.508 to -0.352) for the QPAC1.5.</p><p><strong>Discussion: </strong>We illustrate how contemporary causal inference methods and alternative estimands can be used to account for concurrent analgesic use in pain RCTs in a manner that may result in larger treatment effects.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"11 2","pages":"e1409"},"PeriodicalIF":3.1,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12978825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147445910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term examination of pain and health-related outcomes in people with fibromyalgia before, during, and after COVID-19.","authors":"Benjamin Mosch, Martin Diers","doi":"10.1097/PR9.0000000000001380","DOIUrl":"10.1097/PR9.0000000000001380","url":null,"abstract":"<p><strong>Introduction: </strong>Since the outbreak of COVID-19, many studies have investigated long-term consequences associated to the pandemic. Undoubtedly, restrictions and changes in everyday life during that time have had a broad impact on mental health and well-being, particularly in vulnerable populations, such as chronic pain patients.</p><p><strong>Objectives: </strong>The aim of this study was to examine longitudinal progression of pain-related outcomes in patients with fibromyalgia (FM).</p><p><strong>Methods: </strong>Using a repeated measures design with comparative data acquired before (T1) and during the pandemic (T2), as well as data from a recent survey (T3), this study investigated long-term development of pain symptoms and well-being in FM (N = 75) throughout and beyond the pandemic. For this purpose, longitudinal changes of clinical parameters, such as pain severity, disability, and depressive mood, as well as self-perceived changes of pain, anxiety, depression, and physical activity were assessed.</p><p><strong>Results: </strong>Patients displayed significant self-perceived worsening of pain compared with both preceding survey periods. However, these self-perceived changes were not reflected in longitudinal increases of pain values. Pain-related interference, perceived helplessness, and social activity levels were significant predictors of pain severity at T3, when using only T3 determinants as predictors. On the other hand, with regard to the prepandemic and pandemic period, past pain levels (T1, T2) and affective distress experienced at T2 were significant predictors of T3 pain.</p><p><strong>Conclusions: </strong>These findings emphasize the importance of psychosocial factors for the long-term progression of pain symptoms. In addition, our data suggest remarkable long-term stability of pain symptoms, despite repeated evidence for a self-perceived worsening of pain.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"11 1","pages":"e1380"},"PeriodicalIF":3.1,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12721768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145821790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of cognitive behavioral therapy on attention in patients with fibromyalgia: a randomized controlled trial.","authors":"Savannah Kazemipour, Jolin B Yamin, David Moore, Asimina Lazaridou, Myrella Paschali, Vitaly Napadow, Robert R Edwards, Samantha M Meints","doi":"10.1097/PR9.0000000000001378","DOIUrl":"10.1097/PR9.0000000000001378","url":null,"abstract":"<p><strong>Introduction: </strong>More than three-fourths of people with fibromyalgia complain of cognitive difficulties, including memory and attention problems, which result in impaired job performance and disability. Cognitive behavioral therapy (CBT) is efficacious in treating people with attention deficits, depression, anxiety, and chronic pain (eg, fibromyalgia).</p><p><strong>Objectives: </strong>In this study, we examined the efficacy of CBT for improving attention in patients with fibromyalgia.</p><p><strong>Methods: </strong>Sixty-nine women with fibromyalgia (M = 42; SD = 13) were randomly assigned to receive CBT or an education control, and completed computer-based attention tasks and surveys at baseline (before receiving treatment) and at the follow-up (after receiving 8 treatment sessions). We hypothesized that CBT would lead to greater improvement in attention compared with fibromyalgia education. We conducted repeated-measures analyses of variance to examine the effects of time (pre- vs postintervention) and whether CBT resulted in greater improvement (time × condition effects) for attention span, attentional switching, and divided attention.</p><p><strong>Results: </strong>Results indicated an effect of time such that patients in both groups improved from baseline to follow-up for attention span (F = 8.26, <i>P</i> = 0.01) and switch cost response time (F = 4.45, <i>P</i> = 0.04). However, the time by condition interaction was not significant (<i>P</i>s > 0.05), indicating that improvement in attentional performance did not differ across intervention groups.</p><p><strong>Conclusion: </strong>Our results support the possibility of practice effects such that completing tasks that engage attentional processes could serve as potential interventions for attentional deficits observed in fibromyalgia.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"11 1","pages":"e1378"},"PeriodicalIF":3.1,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12705048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: CellKine clinical trial: first report from a phase 1 trial of allogeneic bone marrow-derived mesenchymal stem cells in subjects with painful lumbar facet joint arthropathy: Erratum.","authors":"Dan Yan, Abba C Zubair, Michael D Osborne, Robert Pagan-Rosado, Jeffrey A Stonec, Vance T Lehman, Nisha C Durand, Eva Kubrova, Zhen Wang, Drew M Witter, Meghan M Baer, Gabriela C Ponce, Alfredo Quiñones-Hinojosa, Wenchun Qu","doi":"10.1097/PR9.0000000000001362","DOIUrl":"10.1097/PR9.0000000000001362","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1097/PR9.0000000000001181.].</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 6","pages":"e1362"},"PeriodicalIF":3.1,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12643581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationships between proinflammatory cytokines and depressive symptoms in adolescents with chronic pain.","authors":"Emma F Gaydos, Katrina Huft, Emma Biggs, Sarah Nelson, Laura E Simons","doi":"10.1097/PR9.0000000000001365","DOIUrl":"10.1097/PR9.0000000000001365","url":null,"abstract":"<p><strong>Objective: </strong>Depressive symptoms and chronic pain commonly co-occur among adolescents and share similar proposed underlying processes, including elevation of proinflammatory cytokines. In this study, we investigate how profiles of 4 commonly measured proinflammatory cytokines (IL-1β, IL-6, IL-8, and TNF-α) differ between adolescents with primary chronic pain disorders and pain-free peers. We explored relationships between these cytokines and depressive symptoms, perceived distress (PD), pain severity, functional disability (FD), pain catastrophizing (Pcat), and fear of pain (FOP). Potential mediating effects of cytokines on the relationship between depressive symptoms and FD were also examined.</p><p><strong>Methods: </strong>Differences in cytokine profiles between groups were compared through <i>t</i>-tests. Relationships between cytokine profiles and outcomes were assessed through partial correlations. Bootstrapping mediation analysis assessed whether cytokines mediated the relationship between depressive symptoms and functional disability. Our sample included 78 youth (chronic pain n = 54, <i>M</i>age = 14 years; pain-free n = 24; <i>M</i>age = 16 years).</p><p><strong>Results: </strong>We found that (1) IL-6 levels were higher among adolescents with chronic pain than pain-free peers; (2) higher IL-1β and IL-6 levels were associated with greater PD among adolescents with and without pain; (3) among the pain group, higher IL-6 levels were associated with greater PD, pain severity, and FD; (4) among the pain group, higher IL-1β levels were associated with greater depressive symptoms, PD, Pcat, and FOP. Mediation effects were not significant.</p><p><strong>Conclusion: </strong>Our findings suggest that IL-1β and IL-6 play critical roles in the pain experience. Interleukin-6 is more strongly associated with physical symptoms, and IL-1β is more related to fear-avoidance.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 6","pages":"e1365"},"PeriodicalIF":3.1,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12643753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to De Paepe et al.","authors":"Rod S Taylor, Rui V Duarte","doi":"10.1097/PR9.0000000000001349","DOIUrl":"10.1097/PR9.0000000000001349","url":null,"abstract":"","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 6","pages":"e1349"},"PeriodicalIF":3.1,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12643732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Capturing individual experiences: advancing core outcome sets in pain. Comment on Taylor et al. (2024).","authors":"Annick L De Paepe, Esther M Pogatzki-Zahn, Whitney Scott","doi":"10.1097/PR9.0000000000001348","DOIUrl":"10.1097/PR9.0000000000001348","url":null,"abstract":"","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 6","pages":"e1348"},"PeriodicalIF":3.1,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12643727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-lasting and fast methylglyoxal-scavenging peptide CycK(Myr)R₄E alleviates chronic pain in type 2 diabetic mice.","authors":"Paramita Basu, Diogo F S Santos, Nina Gakii, Margaret R Gralinski, Ryan B Griggs, Sebastian Brings, Thomas Fleming, Keiichiro Susuki, Bradley K Taylor","doi":"10.1097/PR9.0000000000001312","DOIUrl":"10.1097/PR9.0000000000001312","url":null,"abstract":"<p><strong>Introduction: </strong>Pathological levels of methylglyoxal (MG), a reactive dicarbonyl product of glucose, contribute to major neurological complications associated with type II diabetes, including chronic neuropathic pain. Strategies to target elevated MG have included small molecule MG scavengers, but scavenger deficiencies in proteolytic stability and onset of scavenging activity have precluded clinical translation. To address this gap, we developed a long-lasting and highly reactive cyclic peptide CycK(Myr)R₄E, and here evaluated its antihyperalgesic efficacy in the db/db mouse model of type II diabetes painful diabetic neuropathy.</p><p><strong>Objectives: </strong>To test the hypothesis that CycK(Myr)R₄E can reduce behavioral and molecular signs of painful diabetic neuropathy.</p><p><strong>Methods: </strong>We assessed heat hypersensitivity as an index of hyperalgesia, and touch-evoked expression of phosphorylated extracellular signal-regulated kinase as a measure of neuronal activity in spinal cord dorsal horn.</p><p><strong>Results: </strong>We report that a single systemic injection of CycK(Myr)R₄E (3 mg/kg) reversed heat hypersensitivity. Repeated systemic injection of CycK(Myr)R₄E (0.125 mg/kg, 3 times per week, 6-12 weeks of age) prevented heat hypersensitivity and reduced stimulus-evoked phosphorylated extracellular signal-regulated kinase.</p><p><strong>Conclusion: </strong>These studies promote CycK(Myr)R₄E as the most promising MG scavenger for the prevention and treatment of hyperalgesia in type 2 diabetic neuropathic pain.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 5","pages":"e1312"},"PeriodicalIF":3.1,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12348387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144849595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity and contributions to pain from the central aspects of pain questionnaire in rheumatoid arthritis.","authors":"Stephanie Louise Smith, Vasileios Georgopoulos, Onosi Sylvia Ifesemen, Richard James, Eamonn Ferguson, Richard J Wakefield, Deborah Wilson, Philip Buckley, Dorothy Platts, Susan Ledbury, Ernest Choy, Tim Pickles, Zoe Rutter-Locher, Bruce Kirkham, David Andrew Walsh, Daniel F McWilliams","doi":"10.1097/PR9.0000000000001295","DOIUrl":"10.1097/PR9.0000000000001295","url":null,"abstract":"<p><strong>Introduction: </strong>The central nervous system (CNS) contributes to pain perception across musculoskeletal conditions. The central aspects of pain (CAP) questionnaire captures a single score associated with quantitative sensory testing (QST) evidence of CNS dysfunction validated in knee osteoarthritis.</p><p><strong>Objectives: </strong>Given the different pathophysiology of rheumatoid arthritis (RA), an inflammatory polyarthritis, this cross-sectional study assessed CAP's psychometric properties and its association with pain in RA.</p><p><strong>Methods: </strong>Adults with RA were recruited from Nottinghamshire, London, and Cardiff. Participants completed CAP and reported pain using a numerical rating scale. A subgroup underwent additional assessments, including quantitative sensory testing (QST; Pressure Pain detection Threshold, Temporal Summation, Conditioned Pain Modulation), Disease Activity Score-28, C-reactive protein, questionnaires addressing pain and related characteristics, and Central Sensitization Inventory short form (CSI-9). Cronbach alpha, confirmatory factor (CFA), and Rasch measurement theory assessed CAP's reliability and validity. Multivariable linear regression modelled contributions to pain by inflammation indices and CAP or CSI-9.</p><p><strong>Results: </strong>The 380 participants (73% female, median 63 years) reported average pain over the past 4 weeks of 6/10 and a CAP score of 9/16. Central aspects of pain demonstrated acceptable reliability (ICC_(2,1) = 0.71), CFA fit (comparative fit index = 0.99, Tucker-Lewis index = 0.99, root mean square error of approximation = 0.034, standardized root mean residuals = 0.03), and internal consistency (α = 0.82). Central aspects of pain was significantly associated with pain (0.50 ≤ β ≤ 0.57) but not QST. Central aspects of pain explained 33% of pain variance, rising to 42% with inflammation, age, sex, and body mass index. Central Sensitization Inventory-9 correlated with pain, not QST and explained less pain variance than CAP.</p><p><strong>Conclusion: </strong>Central aspects of pain is reliable and valid for use with people with RA and explains RA pain variance better than inflammation or CSI-9.</p>","PeriodicalId":52189,"journal":{"name":"Pain Reports","volume":"10 4","pages":"e1295"},"PeriodicalIF":3.1,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}